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Abstract: Polypeptide multilayer nanoﬁ  lms were prepared using electrostatic layer-by-layer 
self-assembly nanotechnology. Small charged drug molecules (eg, cefazolin, gentamicin, and 
methylene blue) were loaded in polypeptide multilayer nanoﬁ  lms. Their loading and release 
were found to be pH-dependent and could also be controlled by changing the number of ﬁ  lm 
layers and drug incubation time, and applying heat-treatment after ﬁ  lm formation. Antibiotic-
loaded polypeptide multilayer nanoﬁ  lms showed controllable antibacterial properties against 
Staphylococcus aureus. The developed biodegradable polypeptide multilayer nanoﬁ  lms are 
capable of loading both positively- and negatively-charged drug molecules and promise to serve 
as drug delivery systems on biomedical devices for preventing biomedical device-associated 
infection, which is a signiﬁ  cant clinical complication for both civilian and military patients.
Keywords: polypeptide, self-assembly, polyelectrolyte multilayer, nanoﬁ  lm, charged molecule, 
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Introduction
Biomedical devices are indispensable in the care of patients. However, biomedical 
device-associated infection is a signiﬁ  cant clinical complication. In orthopedics, 
infection prevention is one of the major goals of injury management. Infection rates 
are 7%–9% for elbow replacements and 1%–2% for hip replacements,1 and patients 
with open fractures have a high risk of infection due to bacterial contamination and 
soft tissue damage. The incidence of Gustilo grade III open fractures may exceed 
30%2,3 and 2%–15% (or higher) of combat-related extremity injuries with developed 
osteomyelitis.4  To reduce the risk of biomedical device-associated infection, attention 
has turned recently to developing drug-containing ﬁ  lms on biomedical devices,5–10 as 
such ﬁ  lms can enhance the device’s speciﬁ  c functions including ﬁ  ghting infection and 
promoting wound-healing.5,7,10 For instance, dip coating,8 spin coating,9 spray coating,6 
and covalent conjugation of antibiotics10 have been developed to prepare antimicrobial 
ﬁ  lms on biomedical devices. Much effort has been devoted to controlling drug release 
via manipulating the dissolution or degradation of the ﬁ  lms.
More recently, electrostatic layer-by-layer self-assembly nanotechnology has 
been developed11 and used to construct polyelectrolyte micro- or nanocapsules12,13 
and multilayer ﬁ  lms14,15 for drug delivery. Certain drug molecules, such as active 
proteins, enzymes, nucleic acids, and DNA, have been immobilized into polyelec-
trolyte multilayer ﬁ  lms. The advantages of polyelectrolyte multilayer ﬁ  lms as drug 
delivery systems include: (i) drug molecules can act as either functional drugs or 
components of the ﬁ  lm, and they can also form a stable crosslinking structure with 
other ﬁ  lm component(s) via multivalent interactions (eg, electrostatic or hydrogen-
bonding interactions), (ii) sustained drug release is possible through controlling the 
ﬁ  lm properties,16 (iii) polyelectrolyte multilayer ﬁ  lms have the potential to protect International Journal of Nanomedicine 2009:4 38
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drug molecules from losing their biological functions,17–21 
and (iv) the ﬁ  lm preparation process is simple and can be 
automated.11,14–17,
The drug release behavior of polyelectrolyte multilayer 
films depends on the permeability, the disassembly or 
erosion of the multilayer structure, and other experimental 
variables. A variety of polyelectrolyte multilayer films 
has been studied to control drug release via ionic strength, 
temperature, pH, enzyme, and hydrolytical degradation,12,13 
Hayne and colleagues have bonded a thiol-bearing molecule, 
5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), into multilayers 
and 2-nitro-5-thiobenzoate dianions were released from the 
ﬁ  lms by the breakdown of disulﬁ  de bonds between the DTNB 
and one of the ﬁ  lm components.22 Rubner and colleagues 
have loaded Ketoprofen or cytochalasin D into polyelec-
trolyte multilayers and have shown unique zero-order drug 
release over a period of a few days.23,24 Caruso and Quinn have 
developed thermo-responsive multilayers containing poly-
(N-isopropylacrylamide-co-acrylic acid) and have achieved 
sustained drug release.16 In addition, hydrogels and micelles 
have been introduced into polyelectrolyte multilayers as 
“drug containers” to manipulate drug-loading capacity.25–27 
However, only a few studies are reported on controlling the 
loading and release of small drug molecules.22,28–30 It is still 
challenging to achieve a controllable release of small charged 
drug molecules, probably due to the weak interactions 
between small drug molecules and the ﬁ  lm components. 
All of these have limited the applications of polyelectrolyte 
multilayer ﬁ  lms for controlled drug release, especially on 
biomedical devices. Introducing “binding-sites” with tunable 
properties within nanoﬁ  lms could be very useful in achieving 
controllable drug loading and release in polyelectrolyte mul-
tilayer ﬁ  lms on biomedical devices.
In this work, we prepared polypeptide multilayer 
nanoﬁ  lms using weak polyelectrolytes of poly-L-lysine 
(PLL) and poly-L-glutamic acid (PLGA), and we studied 
the loading and release behavior of small charged drug 
molecules. One advantage of such biodegradable drug release 
systems is that drug “binding-sites” within the multilayer 
nanoﬁ  lms can be created and tuned simply by immersing 
the multilayer nanoﬁ  lms fabricated at one pH into an aque-
ous solution of a different pH. For instance, PLL/PLGA 
multilayer nanoﬁ  lms were prepared at pH 4.0, and positively-
charged drugs including gentamicin and methylene blue 
(MB) were loaded into the multilayer nanoﬁ  lms by immers-
ing the nanoﬁ  lms in a drug-containing solution of a higher 
pH (eg, pH 7.0). Negatively-charged drugs such as cefazolin 
were incorporated into nanoﬁ  lms formed at pH 10.0 by 
incubating the nanoﬁ  lms in a cefazolin-containing solution 
of a lower pH (eg, pH 7.0). We showed that the loading 
and release of small charged (positively and negatively) 
drug molecules could be tuned by changing the number 
of ﬁ  lm layers, the pH of the application environment or 
the pH of drug solutions, and applying post-preparation 
heat-treatment of the nanoﬁ  lms. The driving force of drug 
loading and release from the multilayer nanoﬁ  lms is mainly 
electrostatic interaction, attraction or repulsion, between the 
small charged drug molecules and the charged side-chains 
(binding-sites) of PLL or PLGA. Moreover, we found that 
polypeptide multilayer nanoﬁ  lms loaded with antibiotics 
presented antibacterial properties against Staphylococcus 
aureus (S. aureus). Therefore, the developed approach is 
promising for controlling the loading and release of small 
charged drug molecules and achieving drug release systems 
for preventing biomedical device associated infection.
Materials and methods
Materials
Poly-L-lysine (Mn = 150 kDa), PLGA (Mn = 50 kDa), 
MB, gentamicin, and cefazolin were used (Sigma Aldrich, 
St. Louis, MO). The structures of these polymers and drugs are 
shown in Figure 1, where cefazolin, a widely used antibiotic, 
is a negatively-charged small drug molecule, and gentamicin, 
another common antibiotic, and MB, a dye indicator, are 
positively-charged small molecules. Quartz slides were 
purchased from SPI Supplies, Inc. (West Chester, PA), cut 
into 25 mm × 10 mm × 1 mm, and cleaned by incubating in a 
piranha solution (4:1 H2SO4/H2O2) for 2 h at 80 °C followed 
by rinsing with deionized water. Stainless steel sheets were 
purchased (Small Parts, Inc., Miramar, FL) and cut into discs 
(10 mm × 0.25 mm), which were ultrasonicated in a 2% 
sodium dodecyl sulphate (SDS) solution for 30 min, washed 
in deionized water, and rinsed with an ethanol–NaOH solution 
and deionized water.
Buffer solutions in the pH range 4.0–10.0 were used 
throughout this study. Buffer solutions of pH 7.0–10.0 were 
prepared using 50 mM glycine–NaOH and buffer solutions 
of pH 4.0–7.0 were prepared using 10 mM Tris-HCl, 10 mM 
NaAc, and 130 mM NaCl. Gentamicin (10 mg/mL) and 
MB (3 mg/mL) solutions were prepared in Tris-HCl buffer 
solutions of pHs 4.0, 5.0, and 7.0. Cefazolin was dissolved 
in the glycine–NaOH buffer solutions of pHs 7.0, 8.0, and 
9.0 at a concentration of 10 mg/mL. PLL (1 mg/mL) and 
PLGA (1 mg/mL) solutions were prepared by dissolving 
PLL and PLGA in the buffer solutions of pHs 4.0, 5.0, 7.0, 
9.0, and 10.0.International Journal of Nanomedicine 2009:4 39
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Assembly of polypeptide multilayer 
nanoﬁ  lms
Polypeptide multilayer nanoﬁ  lms were prepared at pHs 4.0, 
5.0, 7.0, 9.0, and 10.0 using a dipping-machine (Riegler and 
Kirstein GmbH, Berlin, Germany); all the aqueous media used 
were of the same pH for the same sample. In brief, pre-cleaned 
quartz slides or stainless steel discs were dipped in a PLL 
solution for 20 min followed by rinsing with corresponding 
buffer solution for 3 min and drying with air. The samples 
were then dipped in a PLGA solution for 20 min, rinsed 
with buffer solution for 3 min, and dried with air. These two 
dipping processes, ie, dipping in PLL and PLGA solutions, 
were referred to as one deposition cycle. By repeating the 
deposition cycle, polypeptide multilayer nanoﬁ  lms, (PLL/
PLGA)n, were prepared where n is the number of deposition 
cycles or bilayers.
The formation of polypeptide multilayer nanoﬁ  lms on 
quartz slides was examined using UV-vis spectrometry. 
Images of PLL/PLGA multilayer nanoﬁ  lms were obtained 
using atomic force microscopy (AFM, PicoSPM® II, Tempe, 
AZ) operating in a tapping mode with a silicon nitride 
cantilever tip. The growth of multilayer nanoﬁ  lms on stainless 
steel discs with bilayers was measured using ellipsometry 
(M-2000, JA Woollam Co., Lincoln, NE).
Post-preparation heat-treatment 
of polypeptide multilayer nanoﬁ  lms
Polypeptide multilayer nanoﬁ  lms, (PLL/PLGA)10 and (PLL/
PLGA)20, on quartz slides were treated at 120 °C in a vacuum 
oven (Isotemp Model 281, Fisher Scientiﬁ  c, Pittsburgh, PA) 
for 4 h. The vacuum applied was 380 Torr.
Stability of polypeptide multilayer 
nanoﬁ  lms
The stability of polypeptide multilayer nanoﬁ  lms in aqueous 
media was tested. In one set of studies, (PLL/PLGA)20 ﬁ  lms 
on quartz slides were assembled at pHs 4.0, 7.0, and 10.0, 
and then incubated in a phosphate-buffered saline (PBS) of 
pH 7.0. In another set of experiments, (PLL/PLGA)20 ﬁ  lms 
prepared at pH 10.0 on quartz slides were incubated in PBS 
solutions of pHs 4.0, 7.0, and 9.0. After incubating for 0, 0.5, 
2.5, 8, 24, 48, 96, and 192 h, the samples were dried and their 
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Figure 1 Structures of studied polypeptides and drugs.International Journal of Nanomedicine 2009:4 40
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absorbances in the range of 190–290 nm were recorded using 
UV-vis spectrometry. All the data were averaged from three 
measurements. The absorbances of the same polypeptide 
multilayer nanoﬁ  lm were compared between the time points 
studied.
Antibiotic- and MB-loading in polypeptide 
multilayer nanoﬁ  lms
The loading of positively- and negatively-charged small drug 
molecules and drug models in polypeptide multilayer nano-
ﬁ  lms was studied. The inﬂ  uences of number of ﬁ  lm layers 
as well as the drug-loading time and drug solution pH were 
investigated. Polypeptide multilayer nanoﬁ  lms prepared at 
pHs 4.0, 5.0, and 7.0 were used to load positively-charged 
drug molecules (ie, gentamicin and MB), and those at pHs 
7.0, 9.0, and 10.0 were used to load negatively-charged 
drug molecules (ie, cefazolin). To determine the effect of 
drug solution pH on drug loading, (PLL/PLGA)20 ﬁ  lms 
prepared at pH 4.0 were incubated in MB solutions of pHs 
4.0, 5.0, and 7.0, and (PLL/PLGA)20 ﬁ  lms prepared at pH 
10.0 were immersed in cefazolin solutions of pHs 7.0, 8.0, 
9.0, and 10.0.
In general, polypeptide multilayer nanoﬁ  lms on quartz 
slides were incubated in the corresponding drug solutions at 
ambient temperature. At time periods of 2, 5, 10, 20, 40, and 
60 min, the samples were rinsed with deionized water and 
dried with N2 gas followed by UV-vis absorbance measure-
ments. The loading of cefazolin, gentamicin, and MB was 
determined by measuring the absorbance at 270 nm, 270 nm, 
and 665 nm, respectively, using UV-vis spectrometry.28,29
In order to obtain the total loading amounts of cefazolin, 
gentamicin, and MB in polypeptide multilayer nanoﬁ  lms, 
the drug-loaded samples were ultrasonicated in 1 mL PBS 
for 30 min, and the ultrasonication process was repeated 
three or more times until no peak absorbance referring to the 
corresponding drugs on quartz slides could be observed using 
UV-vis spectrometry. The drug concentration in the PBS was 
analyzed by recording the peak absorbance of the drugs. Raw 
data were converted to concentration of drug (Cn, μg/mL) 
referring to the standard curves we obtained (data not shown). 
The drug released into the PBS solutions (Mn, μg/cm2) was 
calculated from an equation: Mn = Cn × V/An, where V is 
the total volume of the PBS and An is the surface area of the 
nanoﬁ  lms on substrates. The total drug loaded in polypep-
tide multilayer nanoﬁ  lms was determined as the cumulative 
amount of drugs released during the ultrasonication processes. 
It is worth noting that the peak absorbance of gentamicin 
at 270 nm was observed in gentamicin-loaded polypeptide 
multilayer nanoﬁ  lms but the absorbance of the released 
gentamicin in the PBS solutions was hard to detect. As a result, 
the actual amount of gentamicin loaded was not reported in 
this study.
In vitro drug release from polypeptide 
multilayer nanoﬁ  lms
Drug-loaded polypeptide multilayer nanoﬁ  lms on quartz 
slides were incubated in 10 mL PBS of a certain pH (eg, pHs 
4.0, 5.0, 7.0, 9.0, or 10.0). 0.6 mL of PBS solution was taken 
at a certain time period and 0.6 mL of fresh PBS was added to 
keep the volume of the release medium constant. The sample 
solutions of cefazolin and MB were analyzed using UV-vis 
spectrometry by measuring their absorbance at 270 nm and 
665 nm, respectively. The total drug release (μg/cm2) was 
calculated as detailed before.
S. aureus Kirby–Bauer disk diffusion assay
A modiﬁ  ed Kirby–Bauer technique was used to assess the 
antibacterial activity of polypeptide multilayer nanoﬁ  lms 
loaded with antibiotics.31,32 A clinical isolate S. aureus was 
grown overnight in Mueller–Hinton broth, and the turbidity 
was adjusted to 0.5 McFarland. A cotton swab was dipped in 
the S. aureus suspension and rubbed across the surface of a 
Mueller–Hinton blood agar plate. Cefazolin- and gentamicin-
loaded polypeptide multilayer nanoﬁ  lms on stainless steel 
discs were inserted parallel to the agar plate surface. The 
plates were inverted and incubated at 37 °C without shaking 
for 24 h before observation. The diameters of the zones of 
inhibition were measured six times from different directions, 
and the experiments were repeated at least three times. The 
average diameters of the zones were calculated.
Results
Growth curve and stability of PLL/PLGA 
multilayer nanoﬁ  lms
The formation of PLL/PLGA multilayer ﬁ  lms was examined 
using UV-vis spectrometry, ellipsometry, and AFM. Figure 2a 
shows that the absorbance of PLL/PLGA multilayer ﬁ  lms on 
quartz slides increased with increasing number of bilayers. In 
the pH values studied (ie, pH 4.0, 7.0, and 10.0), the smallest 
increase in absorbance was observed in the multilayer ﬁ  lms 
constructed at pH 7.0. Figure 2b presents the thickness of 
polypeptide multilayer ﬁ  lms. One can see that the thickness 
growth of PLL/PLGA multilayer ﬁ  lms increased linearly with 
an increasing number of deposition bilayers. Similar to the 
UV-vis absorbance data, the least thickness was observed in International Journal of Nanomedicine 2009:4 41
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the multilayer ﬁ  lms constructed at pH 7.0 and the greatest 
thickness in the ﬁ  lms prepared at pH 10.0. The thickness 
per layer of the PLL/PLGA multilayer ﬁ  lms prepared at 
pHs 4.0, 7.0 and 10.0 were 4.3 ± 0.3 nm, 3.4 ± 0.1 nm, and 
5.9 ± 0.2 nm, respectively.
The surface morphology of polypeptide multilayer 
nanoﬁ  lms formed at pHs 4.0, 7.0, and 10.0 was examined 
using AFM (Figure 2b insets). Particulate domains were 
observed. The size of the particulate domains of the nanoﬁ  lms 
prepared at pH 7.0 was around tens of nanometers and was 
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much smaller than those of the nanoﬁ  lms assembled at pHs 
4.0 and 10.0.
One concern in developing polyelectrolyte multilayer 
ﬁ  lms is their stability. Our stability studies of the PLL/PLGA 
nanoﬁ  lms in aqueous solutions showed no obvious changes 
in absorbance (data not shown) in the wavelength range of 
190–290 nm after more than one week at all the pH values 
studied (ie, pH 4.0, 7.0, and 9.0). This means that PLL/PLGA 
multilayer nanoﬁ  lms are stable and can tolerate pH shifts in 
our drug loading and release processes.
Tunability of drug loading in PLL/PLGA 
multilayer nanoﬁ  lms
The inﬂ  uence of pH at which the multilayer nanoﬁ  lms were 
prepared and time of incubation on drug loading was studied 
in (PLL/PLGA)20 nanoﬁ  lms (Figure 3). It was found that the 
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loading of drugs increased with the incubation time and 
the loading of cefazolin and MB could reach their maximum 
loading (ie, capacity) within 10 and 20 min, respectively. 
(PLL/PLGA)20 nanoﬁ  lms formed at different pHs showed 
different drug-loading capacities. More drugs were captured 
in the nanoﬁ  lms prepared at a pH away from pH 7.0 than at 
pH 7.0, and loading was faster in the nanoﬁ  lms assembled at 
pHs 10.0 and 4.0 than at pH 7.0. Cefazolin-loading capacity in 
the nanoﬁ  lms formed at pH 10.0 was ∼330 μg/cm2; it was the 
highest and it was almost six times that of nanoﬁ  lms prepared 
at pH 7.0 (∼60 μg/cm2). Similarly, the MB-loading capacity 
in (PLL/PLGA)20 nanoﬁ  lms assembled at pH 4.0 was about 
ten times that in the nanoﬁ  lms prepared at pH 7.0.
The inﬂ  uence of drug solution pH on drug loading was 
also investigated. Figure 4 shows that more cefazolin was 
loaded in (PLL/PLGA)20 nanoﬁ  lms at a lower pH in the range 
of pH 7.0–10.0, and more MB was loaded at a higher pH in 
the range of pH 4.0–7.0. Cefazolin-loading capacity at pH 7.0 
was about four times that at pH 9.0. Loading of cefazolin at 
pH 10.0 was not detected and the loading capacity of MB at 
pH 7.0 was about sixteen times that at pH 4.0.
Figure 5a presents the drug-loading capacity versus 
bilayers of (PLL/PLGA)n nanoﬁ  lms. The amounts of drugs, 
either cefazolin or MB, loaded increased approximately 
linearly with an increasing number of bilayers.
The inﬂ  uence of post-preparation heat-treatment on drug 
loading is shown in Figure 5b. After heat-treatment at 120 °C 
for 4 h, both (PLL/PLGA)10 and (PLL/PLGA)20 nanoﬁ  lms 
had ∼30% increase in drug loading.
In addition, Figure 6 shows that gentamicin was loaded 
into PLL/PLGA multilayer nanoﬁ  lms within 20 to 40 min, 
and gentamicin and MB, both positively-charged, had similar 
drug-loading kinetics in (PLL/PLGA)20 nanoﬁ  lms.
Tunability and kinetics of drug release 
from PLL/PLGA multilayer nanoﬁ  lms
Environmental conditions (eg, pH) inﬂ  uenced the drug release 
from polypeptide multilayer nanofilms. We studied the 
release of cefazolin and MB from (PLL/PLGA)20 nanoﬁ  lms 
in a wide range of pH values. Figure 7 shows that more 
cefazolin was released at a higher pH than at a lower pH in 
the pH range 7.0–10.0; the amount of cefazolin released at pH 
10.0, ∼340 μg/cm2, was about twice that released at pH 7.0, 
∼190 μg/cm2. Also, more MB was released at a lower pH than 
at a higher pH in the pH range 4.0–7.0.
Moreover, the number of ﬁ  lm bilayers, the pH at which the 
nanoﬁ  lms were prepared, and post-preparation heat-treatment 
inﬂ  uenced drug release from polypeptide multilayer nanoﬁ  lms. 
The number of ﬁ  lm bilayers inﬂ  uenced the drug release behavior. 
Figure 8a shows that there was a burst release in the ﬁ  rst few 
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hours (mainly the ﬁ  rst hour) in all the cefazolin-loaded samples. 
Up to 95% cefazolin was released from 2- and 5-bilayer PLL/
PLGA nanoﬁ  lms within 48 h, and 85% and 75% were released 
from the 10- and 20-bilyer PLL/PLGA nanoﬁ  lms, respectively. 
More cefazolin was released from a higher number of bilayers of 
nanoﬁ  lms. For instance, 50, 90, 180, and 250 μg/cm2 cefazolin 
were released at 48 h from 2, 5, 10, and 20-bilayer PLL/PLGA 
nanoﬁ  lms, respectively. Similarly, there was a burst release in 
the ﬁ  rst few hours in MB-loaded PLL/PLGA multilayer nano-
ﬁ  lms, and more MB was released with an increasing number 
of bilayers (Figure 8b).
Figure 9 shows that the pH at which PLL/PLGA nanoﬁ  lms 
were prepared also affected drug release. More cefazolin was 
released from (PLL/PLGA)20 nanoﬁ  lms assembled at a higher 
pH in the pH range 7.0–10.0, and more MB was released 
from (PLL/PLGA)20 nanoﬁ  lms deposited at a lower pH in 
the pH range 4.0–7.0.
In addition, post-preparation heat-treatment inﬂ  uenced 
drug release (Figure 10). A greater amount of cefazolin was 
released from heat-treated samples than from untreated ones. 
Meanwhile, the heat-treatment slowed drug release from the 
PLL/PLGA nanoﬁ  lms. Up to 80% of loaded cefazolin was 
released in the ﬁ  rst 24 h from the 10- and 20-bilayer PLL/PLGA 
nanoﬁ  lms without heat-treatment, while approximately 67% 
and 60% was released from the heat-treated 10- and 20-bilayer 
PLL/PLGA nanoﬁ  lms, respectively (Figure 10 inset).
Kirby–Bauer assays
Studies were conducted to evaluate the antibacterial effects 
of cefazolin- and gentamicin-loaded polypeptide multilayer 
nanoﬁ  lms. Figure 11a shows that the average diameter of zone 
of inhibition increased with increasing ﬁ  lm bilayers. The discs 
with cefazolin had a zone of inhibition of 18.8 ±   0.8 mm, 
20.7 ± 0.9 mm, and 23.9 ± 0.8 mm, respectively, for 5, 10, and 
20-bilayer PLL/PLGA nanoﬁ  lms. The average zone diameters, 
for 5, 10, and 20-bilayers, of gentamicin-loaded PLL/PLGA 
nanoﬁ  lms were 20.2 ± 1.0 mm, 23.6 ± 0.7 mm, and 27.0 ± 
0.9 mm, respectively. The cefazolin- and gentamicin-loaded 
20-bilayer PLL/PLGA nanoﬁ  lms assembled at different pHs 
also showed different antibacterial activity (Figure 11b). The 
average zone diameters for cefazolin-containing nanoﬁ  lms 
assembled at pH 8.0, 9.0, and 10.0 were 18.3 ± 0.8 mm, 20.5 ± 
1.0 mm, and 23.9 ± 0.8 mm, respectively, and the average 
zone diameters were 17.5 ± 1.1 mm, 22.5 ± 1.0 mm, and 27.0 ± 
0.9 mm for gentamicin-containing (PLL/PLGA)20 nanoﬁ  lms 
deposited at pH 7.0, 5.0, and 4.0, respectively.
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Figure 6 Loading proﬁ  les of gentamicin and MB in (PLL/PLGA)20 nanoﬁ  lms assembled at pH 4.0. Both gentamicin and MB were loaded at pH 7.0. UV-vis absorbances of 
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Discussion
In this study, we developed biodegradable polypeptide 
multilayer nanoﬁ  lms made of two weak polyelectrolytes as 
potential drug release systems on biomedical devices. Our 
developed polypeptide multilayer nanoﬁ  lms on stainless 
steel discs and quartz slides possessed the capability to 
load both negatively- and positively-charged small drug 
molecules, and the drug loading and release were tunable 
and pH-dependent.
Mechanism of pH-dependent 
drug loading and release
Compared to strong polyelectrolytes, such as poly(dially
ldimethylammonium chloride) (PDDA) and poly(styrene 
sulfonate) (PSS), weak polyelectrolytes such as PLL, 
PLGA, poly(ethyleneimine) (PEI), poly(acrylic acid) 
(PAA), and poly(allylamine hydrochloride) (PAH), may 
present various ionization statuses and surface charges as 
their environmental pH changes. At a pH below or above 
the isoelectric point (pI), a weak polyelectrolyte is partially 
charged and may adopt a coiled structure in polyelectrolyte 
multilayer nanoﬁ  lms due to the decrease in charge repulsion 
among themselves.13,20 The coil-structured polymer contains 
uncharged segments that may be converted to be charged 
(“binding sites”) if the environmental pH is switched to 
a value at which the weak polyelectrolyte becomes more 
ionized. As a result, binding sites within multilayers made 
of weak polyelectrolytes can be created for capturing 
oppositely-charged drug molecules.
In our study, we prepared PLL/PLGA multilayer 
nanoﬁ  lms using electrostatic layer-by-layer self-assembly 
based on alternative deposition of PLL and PLGA on a 
substrate. Mechanisms of drug loading and release from the 
developed PLL/PLGA multilayer nanoﬁ  lms are proposed 
in Figure 12. PLL and PLGA are weak polyelectrolytes; 
PLGA possesses a net negative charge at a pH higher than 
pH 2.6, the pI of PLGA,33,34 and PLL presents a net posi-
tive charge at a pH lower than its pI, pH 12.5.32 Therefore, 
in the multilayer ﬁ  lms formed in an acid solution, eg, 
pH 4.0, PLGA is partially charged and adopts a coiled 
structure (Figure 12 top part), and its net charge decreases 
as pH decreases in the pH range 2.6–7.0. This results in 
more deposition of PLGA and thicker ﬁ  lms at pH 4.0 than 
at pH 7.0; PLL/PLGA multilayer nanoﬁ  lms assembled at 
pH 4.0 presented a higher absorbance and higher thickness 
than those deposited at pH 7.0 (Figure 2). When incubating 
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Figure 7 Effects of environmental pH on release of cefazolin and MB from polypeptide multilayer nanoﬁ  lms. Cefazolin was released in PBS solutions of pHs 7.0, 9.0, and 10.0 for 
48 h, and MB was released in PBS solutions of pHs 4.0, 5.0, and 7.0 for 48 h. Cefazolin was released from (PLL/PLGA)20 nanoﬁ  lms that were assembled at pH 10.0 and loaded 
with cefazolin at pH 7.0 for 20 min. MB was released from (PLL/PLGA)20 nanoﬁ  lms that were prepared at pH 4.0 and loaded with MB at pH 7.0 for 20 min.
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Figure 8 Release proﬁ  les of (a) cefazolin and (b) MB from polypeptide multilayer nanoﬁ  lms. Both cefazolin and MB were released at pH 7.0. Cefazolin was released from 
PLL/PLGA multilayer nanoﬁ  lms that were assembled at pH 10.0 and loaded with cefazolin at pH 7.0 for 20 min. MB was released from PLL/PLGA multilayer nanoﬁ  lms that 
were prepared at pH 4.0 and loaded with MB at pH 7.0 for 20 min. The inset presents the release, up to 336 h, of cefazolin from (PLL/PLGA)20 nanoﬁ  lms.
Abbreviations: MB, methylene blue; PLGA, poly-L-glutamic acid; PLL, poly-L-lysine.
PLL/PLGA multilayer nanoﬁ  lms prepared at pH 4.0 in a 
drug solution of pH 7.0, where both PLL and PLGA are 
highly ionized, the uncharged side chains of PLGA in the 
nanoﬁ  lms become negatively charged thereby generat-
ing binding sites for positively-charged drug molecules. 
In the pH range 4.0–7.0, the higher the drug solution pH, 
the more binding sites are available and the more drugs can 
be captured. Therefore the capture of drugs is pH-dependent. 
Meanwhile, the release of drugs from PLL/PLGA multi-
layer nanoﬁ  lms is also pH-dependent. When drug-loaded International Journal of Nanomedicine 2009:4 48
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PLL/PLGA multilayer nanoﬁ  lms serve in an environment 
of pH (eg, pH 4.0) lower than the pH (eg, pH 7.0) at which 
the drugs are loaded, the net charge of PLGA reverses and 
PLGA becomes less ionized. This leads to weakening of the 
interactions between the positively-charged drug molecules 
and the negatively-charged PLGA molecules. As a result, 
drugs are released from PLL/PLGA multilayer nanoﬁ  lms.
Similarly (Figure 12 bottom part), PLL/PLGA multilayer 
nanoﬁ  lms assembled at a high pH (eg, pH 10.0) contain partially-
ionized and coil-structured PLL. This allows the PLL/PLGA 
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Figure 9 Effects of pH at which polypeptide multilayer nanoﬁ  lms were assembled on release of (a) cefazolin and (b) MB. Both cefazolin and MB were released at pH 7.0. 
Cefazolin was released from (PLL/PLGA)20 nanoﬁ  lms that were loaded with cefazolin at pH 7.0 for 20 min. MB was released from (PLL/PLGA)20 nanoﬁ  lms that were loaded 
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multilayer nanoﬁ  lms the capability to load negatively-charged 
drugs at pH 7.0, and drug release can be induced in an environ-
ment of a higher pH, eg, pH 8.0, 9.0, or 10.0.
Tunable loading of charged drugs 
in polypeptide multilayer nanoﬁ  lms
The pH at which polypeptide multilayer nanofilms are 
prepared may inﬂ  uence the amount of polymers deposited 
thereby influencing subsequent drug loading. Figure 3a 
shows that the drug-loading capacity of (PLL/PLGA)20 
nanoﬁ  lms prepared at pH 10.0 was approximately six times 
that of nanoﬁ  lms assembled at pH 7.0. The higher loading 
of cefazolin in those nanoﬁ  lms prepared at pH 10.0 was due 
to the higher amount of PLL assembled (corresponding to 
the higher absorbance and increased thickness at pH 10.0 in 
Figure 2) and the more ionization of PLL as the pH changes 
from ﬁ  lm preparation at pH 10.0 to drug loading at pH 7.0, 
compared to those nanoﬁ  lms prepared at pHs 9.0 and 7.0. As a 
result, binding sites on PLL molecules for negatively-charged 
drug molecules were created as the pH shifts from the ﬁ  lm 
preparation pH to the drug-loading pH and more binding sites 
on PLL would be available at a lower pH in the pH range 
7.0–10.0. This is consistent with the increased loading of 
cefazolin in PLL/PLGA multilayer nanoﬁ  lms assembled at 
pH 10.0 than at pHs 9.0 and 7.0 (Figure 3a).
Similarly, (PLL/PLGA)20 nanofilms assembled at a 
lower pH in the pH range 4.0–7.0 would have more PLGA 
deposited, corresponding to higher absorbance and higher 
thickness at pH 4.0 than at pH 7.0 in Figure 2. This thereby 
leads to more binding sites on PLGA for positively-charged 
drug molecules when the drugs are loaded at pH 7.0. As shown 
in Figure 3b, the (PLL/PLGA)20 nanoﬁ  lms formed at a lower 
pH in the pH range of 4.0–7.0 showed higher MB loading. 
Therefore, polypeptide multilayer nanoﬁ  lms assembled at 
different pHs had various capacities for drug loading after 
ﬁ  lm formation.
Meanwhile, the pH at which drugs are loaded could also be 
used to tune drug loading in polypeptide multilayer nanoﬁ  lms. 
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Figure 10 Effects of heat-treatment on cefazolin release from polypeptide multilayer nanoﬁ  lms. Cefazolin was released at pH 7.0. Cefazolin-containing (PLL/PLGA)10 and 
(PLL/PLGA)20 nanoﬁ  lms were assembled at pH 10.0 and loaded with cefazolin at pH 7.0 for 20 min. The inset shows the release in percentage.
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As shown in Figure 4, (PLL/PLGA)20 nanoﬁ  lms prepared at 
pH 10.0 showed different capacities for loading negatively-
charged cefazolin in the pH range 7.0–10.0, and (PLL/
PLGA)20 nanoﬁ  lms prepared at pH 4.0 allowed the tuning of 
positively-charged MB loading in the pH range 4.0–7.0. More 
side chains of PLL, assembled at pH 10.0, became ionized at 
a lower drug-loading pH in the pH range 7.0–10.0, therefore 
more binding sites were available for negatively-charged drug 
molecules and more cefazolin was captured at pH 7.0 than at 
pHs 8.0, 9.0, and 10.0 (Figure 4). At pH 10.0, no absorbance 
for cefazolin was detected in the nanoﬁ  lms, because there was 
no pH shift between ﬁ  lm preparation and drug loading and 
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Figure 11 a) Diameter of zone of inhibition vs number of ﬁ  lm bilayers. Cefazolin-containing PLL/PLGA nanoﬁ  lms were assembled at pH 10.0 and loaded with cefazolin at 
pH 7.0 for 20 min. Gentamicin-containing PLL/PLGA nanoﬁ  lms were assembled at pH 4.0 and loaded with gentamicin at pH 7.0 for 20 min. b) Diameter of zone of inhibition 
vs. pH at which drug-containing (PLL/PLGA)20 nanoﬁ  lms were assembled. (PLL/PLGA)20 nanoﬁ  lms were loaded with cefazolin or gentamicin at pH 7.0 for 20 min.   The diameter 
of control samples was 10.0 mm.
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no binding sites were created; as a result, no cefazolin was 
captured in the nanoﬁ  lms. This may mean that the driving 
force of drug loading in PLL/PLGA multilayers is mainly 
electrostatic attraction. Similarly, the drug solution pH also 
inﬂ  uenced the loading of positively-charged MB, where the 
PLL/PLGA nanoﬁ  lms were assembled at pH 4.0. The change 
in ionization of PLGA led to the capture of more positively-
charged MB at pH 7.0 than at pHs 4.0 and 5.0 (Figure 4). 
The limited loading of MB at pH 4.0 might be related to the 
interaction of MB with the outermost layer, ie, PLGA, of the 
(PLL/PLGA)20 nanoﬁ  lm.
Using the electrostatic layer-by-layer self-assembly 
technique, we can also control the amount of polymers 
deposited and tune the subsequent drug loading by 
manipulating the number of deposition bilayers. Figure 2 
shows that the absorbance and thickness, and thereby the 
amount of polypeptides deposited, increased with increasing 
deposition bilayers. The increase in polypeptide deposition 
could lead to an increase in binding sites and drug loading 
when the pH shifts from the deposition pH to the drug-loading 
pH. As a result, the amounts of cefazolin and MB loaded in 
PLL/PLGA multilayer nanoﬁ  lms increased approximately 
linearly with increasing deposition bilayers (Figure 5a).
In addition, heat-treatment after ﬁ  lm formation may 
influence drug loading. We found that heat-treatment 
after multilayer ﬁ  lm formation led to an increase (∼30%, 
Figure 5b) in cefazolin loading; however, the reason for 
the increase is unknown and will be studied in the future. 
In the literature, heat-treatment led to the formation of 
crosslinkings between polyelectrolyte multilayers due to 
the formation of amide bonds from carboxylic and amine 
groups within polyelectrolyte multilayers,35 and the swelling 
properties of heat-treated ﬁ  lms changed signiﬁ  cantly over 
a wide pH range.36
Tunable drug release from polypeptide 
multilayer nanoﬁ  lms
In previous studies, drug release from polyelectrolyte 
multilayer ﬁ  lms was mainly controlled by manipulating the 
permeability and degradation of the ﬁ  lms. In our study, PLL/
PLGA multilayer nanoﬁ  lms were stable in aqueous solutions 
and could tolerate pH shifts in our drug loading and release 
processes. The release of drug molecules from polypeptide 
multilayer nanoﬁ  lms is mainly due to the change of interaction 
between drug molecules and polypeptide nanoﬁ  lms, and drug 
diffusion.
Figure 12 Mechanisms of pH-dependent drug capture and release from polypeptide multilayer nanoﬁ  lms. PLL/PLGA multilayer nanoﬁ  lms are assembled at a pH (eg, pH 4.0 
or 10.0) away from the drug-loading pH, followed by incubating in a drug (eg, gentamicin, MB, or cefazolin) solution of pH 7.0 and releasing the captured drugs by altering the 
pH of releasing media.
Key:   stretched PLL,   coiled PLL,   stretched PLGA,   coiled PLGA,   positively-charged drug,   negatively-charged drug.
Abbreviations: MB, methylene blue; PLGA, poly-L-glutamic acid; PLL, poly-L-lysine.
pH < 7.0 (eg, 4.0) pH < 7.0 (eg, 4.0) pH 7.0
pH > 7.0 (eg, 10.0)
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By changing the interaction between drug molecules and 
PLL/PLGA multilayer ﬁ  lm components, one can tune drug 
release. As shown in Figure 12, when there is a pH shift from 
drug loading to drug release, the interaction between the drug 
molecules and the corresponding oppositely-charged poly-
peptides changes and drugs can be released. Cefazolin and 
MB were loaded at pH 7.0 and more cefazolin was released 
at pH 10.0 than at a lower pH in the pH range 7.0–10.0. 
More MB was released at pH 4.0 than at a higher pH in 
the pH range 4.0–7.0 (Figure 7), due to the change in the 
interaction between the drug molecules and the corresponding 
oppositely-charged polypeptides. For instance, as the pH 
changed from the drug loading (pH 7.0) to a higher drug 
release pH in the pH range 7.0–10.0, more binding sites of 
PLL were reversed and became uncharged; therefore, more 
cefazolin was released from the nanoﬁ  lms.
Moreover, the history of polypeptide multilayer nanoﬁ  lms 
had a signiﬁ  cant impact on the amount of drugs released. 
Drug release could be tuned by controlling the number of 
ﬁ  lm layers, the pH at which the nanoﬁ  lms were prepared, 
and post-preparation heat-treatment. It was found that more 
drugs (cefazolin and MB) were released from PLL/PLGA 
multilayer nanoﬁ  lms with more bilayers (Figure 8). More 
cefazolin was released from (PLL/PLGA)20 nanofilms 
assembled at pH 10.0 than those assembled at a lower pH 
in the pH range 7.0–10.0, and more MB was released from 
(PLL/PLGA)20 nanoﬁ  lms assembled at pH 4.0 than those 
nanoﬁ  lms prepared at a higher pH in the pH range 4.0–7.0 
(Figure 9). The higher drug release was probably associated 
with the corresponding higher drug loading in the PLL/PLGA 
multilayer nanoﬁ  lms under those conditions (Figure 3). The 
post-preparation heat-treatment also had some effect on drug 
release, as it seemed that heat-treatment slowed drug release 
compared to the control samples (Figure 10 inset). This was 
likely related to the possible crosslinking formation and the 
reduced swelling of polyelectrolyte multilayers in aqueous 
media after heat-treatment.36 The higher release amounts of 
cefazolin after the burst release period was because of higher 
amounts of cefazolin loaded in the nanoﬁ  lms after heat-treat-
ment (Figure 5b).
In vitro antibacterial activity 
against S. aureus
Quantitative assessment of the therapeutic activity of antibi-
otic-loaded polypeptide multilayer nanoﬁ  lms was conducted. 
The diameter of a zone of inhibition provides a quantitative 
measure of the amount of in vitro active antibiotic (eg, 
cefazolin and gentamicin) released and diffused into the agar 
plates. Figure 11 shows that PLL/PLGA multilayer nanoﬁ  lms 
containing cefazolin and gentamicin presented large zones 
of inhibition, and those samples without antibiotics had no 
antibacterial effects. The zone of inhibition became larger 
with increasing number of bilayers; this is because more 
drugs (eg, cefazolin) were loaded and subsequently released 
from the PLL/PLGA multilayer nanoﬁ  lms with more bilayers 
(Figure 5a). The difference in the sizes of zone of inhibition 
in (PLL/PLGA)20 nanoﬁ  lms assembled at different pHs was 
also related to the different amounts of antibiotics loaded and 
released from the PLL/PLGA multilayer nanoﬁ  lms. The more 
antibiotics loaded, the bigger the zone of inhibition. Figure 3 
shows that the (PLL/PLGA)20 nanoﬁ  lms formed at different 
pHs possessed different drug-loading capacities, and more 
cefazolin was loaded at pH 10.0 than at pHs 9.0 and 7.0. As 
a result, a larger zone of inhibition was observed in cefazolin 
loaded (PLL/PLGA)20 nanoﬁ  lms assembled at pH 10.0 than 
at pHs 9.0 and 7.0.
Our studies showed that stainless steel discs coated with 
antibiotic-loaded polypeptide multilayer nanoﬁ  lms exhibited 
in vitro antibacterial activity against S. aureus. Stainless steel 
is one of the commonly used metal implants in orthopedics 
and S. aureus is the most common source of osteomyelitis 
and septic arthritis.37,38 Therefore, the developed antibiotic-
loaded polypeptide multilayer nanoﬁ  lms have the potential to 
prevent orthopaedic device-associated infection, and further 
studies will be carried out to investigate the efﬁ  cacy of such 
antibiotic-loaded nanoﬁ  lms in preventing infection in vivo in 
an open fracture rat model we recently developed.39
Conclusions
A multilayer self-assembly technology was applied to construct 
biodegradable polypeptide multilayer nanoﬁ  lms made of PLL 
and PLGA, which are weak polyelectrolytes that enable the 
ﬁ  ne tuning of drug loading and release after ﬁ  lm formation. 
Our studies showed that the loading kinetics of gentamicin and 
MB, both positively-charged, were very similar. The loading 
and release of both negatively- and positively-charged drug 
molecules (eg, cefazolin, gentamicin, and MB) could be tuned 
by several variables during and after the ﬁ  lm preparation. Such 
variables include the number of deposition layers, pH of ﬁ  lm 
preparation, and post-preparation heat-treatment. The loading of 
drugs (eg, cefazolin and MB) increased approximately linearly 
with an increasing number of layers, and heat-treatment before 
drug loading enhanced the drug-loading capacity. The pH of 
ﬁ  lm preparation also signiﬁ  cantly altered the ﬁ  lm formation 
including surface morphology. In addition, the drug-loading 
pH and the incubation time in the drug solution could be used International Journal of Nanomedicine 2009:4 53
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to tune the amount of drugs that could be loaded, and the pH 
of an application environment also had a signiﬁ  cant impact 
on drug release. The developed antibiotic-loaded polypeptide 
multilayer nanoﬁ  lms presented tunable antibacterial properties 
and potentially have signiﬁ  cant applications in medicine, eg, 
antibacterial drug delivery systems for preventing biomedical 
device-associated infection.
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